Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 29, 2020 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering

SAN DIEGO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
December 22, 2020 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces $8.8 Million Registered Direct Offering

SAN DIEGO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
December 10, 2020 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal Trial

SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
November 23, 2020 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Announces Publication in Cancer Cell of Clinical Data that Provides Molecular Insight into the Mechanism of Action of TRC102 and Patient Populations Most Likely to Respond to Treatment

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
November 16, 2020 09:45 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Submission for Approval of Envafolimab (KN035) with the NMPA in China by its Corporate Partners Alphamab Oncology and 3D Medicines

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
November 10, 2020 16:03 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
November 03, 2020 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON to Report Third Quarter 2020 Financial Results and Company Highlights on November 10, 2020

SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
October 26, 2020 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Announces FDA Orphan Drug Designation for TRC102 in Malignant Glioma, Including Glioblastoma

SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
September 21, 2020 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Highlights Updated Envafolimab Clinical Results in MSI-H/dMMR Colorectal Cancer

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
September 10, 2020 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...